Navigation Links
Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint
Date:11/1/2007

tacyclin therapy delivered four times daily by inhalation has the opportunity to provide incremental benefit to the many patients who are currently receiving oral medications for PAH."

Further review and analysis of the TRIUMPH-1 preliminary results are ongoing. Full data from TRIUMPH-1 will be presented at an upcoming medical meeting and will also be available through the publication of peer-reviewed journal articles.

About Viveta

Viveta is an investigational therapy that has not yet been determined safe or efficacious in humans. Viveta is an inhaled formulation of treprostinil. Treprostinil is a stable synthetic form of prostacyclin. Following regulatory approvals, Viveta will be co-promoted by United Therapeutics' commercialization group, based in Research Triangle Park, North Carolina, and Lung Rx's pulmonary division, based in Silver Spring, Maryland. It is estimated that there are approximately 6,000 physicians in the United States who currently treat their patients with Tracleer and/or Revatio, and such physicians may be able to supplement those treatments with Viveta following regulatory approval.

Conference Call

Lewis J. Rubin, MD, FCCP, the Co-Chair of the TRIUMPH-1 Steering Committee and Professor of Medicine at University of California San Diego Medical Center, will join United Therapeutics' management on a one-hour conference call to answer questions related to TRIUMPH-1.

The teleconference will be held on Thursday, November 1, 2007, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 1-800-603-1777, with international callers dialing 1-706-679-8129. A rebroadcast of the teleconference will be available for one week following the teleconference by dialing 1-800-642-1687, with international callers dialing 1-706-645-9291, and using access code 20811764.

This teleconference is also being web cast and can be accessed via United Therapeutics' website at

SOURCE United Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Man against HIV – new vaccine ready for human trials
2. FDA approves Phase 0 trial which tests experimental drugs on humans
3. Male contraceptive in trial
4. How do patients benefit of clinical trials
5. Glenmark’s new molecule to go through trial
6. Clinical trials need to be more frank
7. First head-to-head trials of once weekly Fosamax and Actonel therapies
8. Hormone Replacement Therapy increases the risk of endometrial cancer
9. Atrial fibrillation predicts for acute ischaemic stroke
10. Spray on contraceptive clears Phase I trial
11. The Indian Government has given the nod to conduct Human volunteer trials inorder to develop preventive AIDS vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 LiveOps, the global ... solutions, announced today that the company has received ... for the creation of a social learning ecosystem ... Hall Group honors companies that have successfully developed ... tools that have helped companies achieve measurable results. ...
(Date:9/16/2014)... 16, 2014 Former Major League Baseball ... undergoing successful heart transplantation surgery at Allegheny General Hospital ... spent most of his 16-year baseball career with the ... commentator for Root Sports Pittsburgh, was discharged home on ... Bailey, MD, surgical director of AGH’s heart transplant program. ...
(Date:9/16/2014)... September 15, 2014Patients with inoperable, early-stage lung cancer ... a five-year survival rate of 40 percent, according ... for Radiation Oncology,s (ASTRO,s) 56th Annual Meeting. Such ... historically conventional RT resulted in poor tumor control ... is an update of RTOG 0236, originally published ...
(Date:9/16/2014)... who tend to be on the heavy side. Researchers ... found that seven in every ten obese adults underestimate ... this mistake much less often. Mothers of overweight or ... as youngsters misjudge their obese mothers, size, says lead ... a study in the Journal of General Internal ...
(Date:9/16/2014)... Poster Discussion abstracts to be presented at the ESMO ... September 2014 at 12:00 (CEST) to give you a ... European medical oncology Congress, under the leading theme Precision ... point where genuinely targeted therapy is now possible for ... we are all working towards a common goal --improved ...
Breaking Medicine News(10 mins):Health News:LiveOps Wins Silver At The 2014 Brandon Hall Group Excellence In Learning Awards For Best Use Of Social/Collaborative Learning 2Health News:LiveOps Wins Silver At The 2014 Brandon Hall Group Excellence In Learning Awards For Best Use Of Social/Collaborative Learning 3Health News:LiveOps Wins Silver At The 2014 Brandon Hall Group Excellence In Learning Awards For Best Use Of Social/Collaborative Learning 4Health News:Former Pittsburgh Pirates Pitcher and Baseball Analyst Kent Tekulve Undergoes Successful Heart Transplant at Allegheny General Hospital 2Health News:Former Pittsburgh Pirates Pitcher and Baseball Analyst Kent Tekulve Undergoes Successful Heart Transplant at Allegheny General Hospital 3Health News:Long-term results of RTOG 0236 confirm good primary tumor control, positive 5-year survival rates 2Health News:Long-term results of RTOG 0236 confirm good primary tumor control, positive 5-year survival rates 3Health News:Poor body size judgement can lead to increased tolerance of obesity 2Health News:ESMO 2014 Congress Preview 2
... Chief Financial Officer, OAKLAND, Calif., July 1 ... ("WorldHeart" or the "Corporation") announced today,that, on June ... NASDAQ Stock,Market stating that the Corporation does not ... requires the Corporation to maintain,a minimum market value ...
... Somanetics Corporation,(Nasdaq: SMTS ) announced today that ... up to an additional $15 million of its common,shares ... shares). Purchases may be,made from time to time in ... timing and amount of, and purposes for, any,purchases will ...
... development, researcher says , , TUESDAY, July 1 (HealthDay News) ... numerous painful interventions, not enough is being done to ... 42,413 painful procedures included in this study, only 2 ... percent received non-pharmacological pain therapy. That means about four ...
... PHILADELPHIA - Researchers at the University of Pennsylvania School ... vaccinate against avian flu. By delivering vaccine via DNA ... minute electric pulse, researchers have immunized experimental animals against ... for the build up of vaccine reserves that could ...
... July 1, 2008 Researchers have found that a ... varieties of adult rheumatoid arthritis is also present in ... responsible gene may be a "master switch" that helps ... Children,s Hospital of Philadelphia reported on the link between ...
... close to patient pinpointed who was likely to progress to ... questionnaire may help in both diagnosing older adults facing dementia ... living. , The Everyday Cognition instrument consists of 39 questions ... , "There have been a number of studies that show ...
Cached Medicine News:Health News:WorldHeart Receives Non-Compliance Letter From NASDAQ Stock Market 2Health News:WorldHeart Receives Non-Compliance Letter From NASDAQ Stock Market 3Health News:Somanetics Announces Share Repurchase Program Increased By $15 Million 2Health News:Newborns in Intensive Care Often Exposed to Pain 2Health News:Newborns in Intensive Care Often Exposed to Pain 3Health News:Penn animal study identifies new DNA weapon against avian flu 2Health News:Penn animal study identifies new DNA weapon against avian flu 3Health News:Pediatric researchers find possible 'master switch' gene in juvenile arthritis 2Health News:Mental Test Spots Alzheimer's Risk 2Health News:Mental Test Spots Alzheimer's Risk 3
(Date:9/16/2014)... Alberta , Sept. 16, 2014  Wearable ... billion industry in less than two years, producing ... the way. A huge opportunity exists for leveraging ... Vivametrica ( http://vivametrica.com/our-video/ ) introduced a first-of-its-kind wearable ... based on years of clinical research linking activity ...
(Date:9/16/2014)...  Eli Lilly and Company (NYSE: ... to co-develop and commercialize AZD3293, an oral beta ... as a potential treatment for Alzheimer,s disease. ... by the accumulation of amyloid plaque in the ... development of beta-amyloid. Inhibiting BACE is expected to ...
(Date:9/15/2014)... PARIS and NEW YORK ... company Pharnext SAS and the Hereditary Neuropathy Foundation (HNF) ... increase the awareness around Charcot-Marie-Tooth (CMT) disease and support ... community. Pharnext will provide financial support ... design and development of a specific section in the ...
Breaking Medicine Technology:Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 2Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 3Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 2Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 3Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 4Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 2Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 3Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 4
... Accelerated Community Oncology,Research Network(TM) (ACORN) will ... Guardian EDC(TM); PACE(TM) PRO System; and,proprietary oncology-focused ... Meeting,June 22-26, in Boston, MA., (Logo: ... 2008 the company announced its Contract Research ...
... iCAD, Inc. (Nasdaq:,ICAD), an industry-leading provider of ... cancer, today announced it has,initiated a clinical study ... partnership with ACR Image Metrix, a subsidiary of ... Image Metrix, having completed the,development portion of the ...
Cached Medicine Technology:ACORN Showcases Oncology CRO, EDC, PRO and Data Warehouse at 44th Annual DIA Meeting 2iCAD Initiates Clinical Study of Its Virtual Colonoscopy CAD in Partnership with ACR Image Metrix 2iCAD Initiates Clinical Study of Its Virtual Colonoscopy CAD in Partnership with ACR Image Metrix 3iCAD Initiates Clinical Study of Its Virtual Colonoscopy CAD in Partnership with ACR Image Metrix 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: